NIH

Sexual Health Supplement Market Size, Share & Trends Analysis Report 2024: Natural Ingredients Lead Market Amid Preference for Organic Products - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Vitamins, Supplements, Other Health, Other Retail, Health, Retail, Dicarboxylic acid, Tablet, Prevalence, Human, Erectile dysfunction, Capsule, Application, COVID-19, Anxiety, Synthetic, NIH, King's College London, Parity, Nature, Safety, ED, Market, Dietary supplement

As per King's College London, ED is estimated that by 2025, 322 million men worldwide are expected to be affected by it.

Key Points: 
  • As per King's College London, ED is estimated that by 2025, 322 million men worldwide are expected to be affected by it.
  • Government-supported sexual health programs indeed have a significant impact on the market.
  • These programs help to increase awareness about sexual health issues, promote safe sex practices and encourage people to take proactive steps to maintain their sexual health.
  • For instance, Australia Department of Health has "Healthysexual" program, which raise awareness about sexual health.

Virpax Pharmaceuticals Reports 2023 Year-End Results

Retrieved on: 
Tuesday, March 26, 2024
Other Health, Pharmaceutical, Medical Devices, Infectious Diseases, Hospitals, Science, Surgery, Veterinary, Biotechnology, Practice Management, Other Science, Health, Research, NCATS, Development, Plaintiff, Post-traumatic stress disorder, Central nervous system, CNS, CRADA, Trauma, Bupivacaine, Chronic pain, NIH, IND, United States bankruptcy court, Bankruptcy, Therapy, FINANCIAL, Pain management, Bangladesh Technical Education Board, Pentagon, Government, Pharmaceutical industry

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2023, and other recent developments.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2023, and other recent developments.
  • “Recently we reported the initial results from the pilot study of Probudur™ performed by the U.S. Army Institute of Surgical Research (USAISR).
  • On November 17, 2023, Virpax announced the resignation of Anthony P. Mack as CEO and Chairman effective immediately.
  • As of December 31, 2023, Virpax had cash of approximately $9.1 million, compared to $19.0 million as of December 31, 2022.

Breakthrough Results of NIH-Sponsored Study of Syn-One Test® as a Skin-Based Diagnostic Tool for Parkinson’s Disease and Related Disorders Published in the Journal of the American Medical Association

Retrieved on: 
Wednesday, March 20, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, JAMA, Lewy body, Diagnosis, Harvard Medical School, American Medical Association, DLB, MSA, Disease, PD, Multiple system atrophy, Alpha-synuclein, Physician, Journal, CND, MD, NIH, Synucleinopathy, Skin, Pathology, Bangladesh Technical Education Board, Medicare, PAF, Dementia, Phosphorylation, Medical imaging

The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.

Key Points: 
  • The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.
  • The proportion of patients with P-SYN was 92.7% in those with PD, 98.2% in those with MSA, 96.0% in those with DLB, and 100% in those with PAF.
  • Future disease-modifying therapies will require convenient, accurate, and precise diagnostic tools to reach the right patients at the right time across a wide array of communities.
  • “The publication of this important NIH-sponsored study is one big step forward with many more milestones to come.”

ATCC Announces Award from the National Cancer Institute to Provide Biospecimen Processing Services and Assays for Cancer Research

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Health, Oncology, Clinical Trials, NCI, BAAS, Research, HHS, National Cancer Institute, Cancer, Doctor of Philosophy, IDIQ, NIH, MBA, PMP, National Institutes of Health, Division, Bangladesh Technical Education Board, Collection, Federal, Federation

This task order, 75N91022D0002.75N91024F00001, under the Division of Cancer Epidemiology and Genetics (DCEG) Field and Biospecimen Support Services’ Multiple Award Indefinite Delivery/Indefinite Quantity (IDIQ), will assist the DCEG’s Biospecimen Activity and Assay Support (BAAS) program by providing biospecimen processing services, as well as molecular and genetic assays, for epidemiologic and clinical cancer research studies.

Key Points: 
  • This task order, 75N91022D0002.75N91024F00001, under the Division of Cancer Epidemiology and Genetics (DCEG) Field and Biospecimen Support Services’ Multiple Award Indefinite Delivery/Indefinite Quantity (IDIQ), will assist the DCEG’s Biospecimen Activity and Assay Support (BAAS) program by providing biospecimen processing services, as well as molecular and genetic assays, for epidemiologic and clinical cancer research studies.
  • “For more than a decade, we have been supporting researchers within the DCEG community by supplying the high-quality biospecimen processing services they need to achieve results and scientific breakthroughs,” said ATCC chairman and CEO Raymond H. Cypess, DVM, PhD.
  • “At ATCC, we offer credible high-quality clinical services that support complex research,” said Rebecca Bradford , MBA, MS, PMP, vice president of Government Programs within ATCC Federal Solutions .
  • “With this new DCEG contract, we continue to provide innovative solutions to support its Biospecimen Activity and Assay Support program.”

USA Patient Registry Software Market Outlook to 2028, Featuring IQVIA, Optum (UnitedHealth Group), Phytel, Dacima Software, FIGmd, Syapse and Pharos Innovations - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Research, Software, University, Infectious Diseases, Education, Hospitals, Health Technology, Genetics, Health Insurance, Data Management, Science, Technology, Clinical Trials, Biotechnology, FDA, Insurance, Health, Professional Services, IOT (Internet of Things), Data Analytics, White House, Federal Government, Practice Management, Managed Care, Other Health, Public Policy, Government, Pharmaceutical, Other Science, Pancreatic disease, Consolidated, Patient, Conditional sentence, Optum, Health information management, Food and Drug Administration, Geography, NPF, RWE, Internet of things, Openclinica, DNA, Policy, Electronic health record, NIH, City, Privacy, CMS, Food, Organization, Prevalence, Federation, Internet, Cancer, Drug development, IQVIA, Evidence-based medicine, RDCRN, Type, Data science, Caregiver, Public health surveillance, Government agency, Registry, EHR, CDC, National Institutes of Health, Bangladesh Technical Education Board, Medicare, Collection, Medical device

The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.

Key Points: 
  • The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.
  • Patient registry software could facilitate data sharing and analysis among these entities, leading to increased adoption
    The patient registry software market in the USA is a part of the broader healthcare information technology sector.
  • Key players in the USA patient registry software market includes IQVIA, Dacima Software, OpenClinica, FIGmd, Dendrite Clinical Systems and various universities conducting medical clinical studies.
  • As technology & data science continue to evolve, the patient registry software market is likely to incorporate more advanced analytics techniques.

Global Cord Blood & Tissue Banking Industry Market Size, Segmentation & Forecast Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2024
Health, Biotechnology, Catalent, Transplant, Cell, Patient, UCB, LifeCell International, Microsoft Exchange Server, Organization, Regenerative medicine, Cryo-Cell International, Spectrum, Disorder, Umbilical cord, Population growth, Stemcell Technologies, Certification, HSCT, NIH, GMP, Cord blood, The Cooper Companies, Safety, Hematopoietic stem cell transplantation, Artivion, DSM-IV codes, Tissue, Research, Acquisition, Cancer, Leukemia, CBR, Cryopreservation, Cerebral palsy, FDA, CBUS, Sickle cell disease, ClinicalTrials.gov, Registry, Amniotic fluid, Hearing loss, GCBC, MNC, Geography

The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.
  • There are now over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The report presents findings on the following topics:
    Rate per cord blood unit in the U.S. and Europe
    Number of clinical trials, number of published scientific papers, and amount of NIH funding for cord blood research
    Number and types of patents for cord blood, cord tissue, and placental products
    The report presents a comprehensive analysis of the global cord blood and tissue banking market.

Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Venture Capital, Manufacturing, Finance, Pharmaceutical, Professional Services, Oncology, Practice Management, Mental Health, Research, Science, Other Manufacturing, COVID-19, CDMO, Patient, Psychological abuse, NIH, Clinical trial, Ground substance, National Institutes of Health, API, NCE, Pain management, Bangladesh Technical Education Board, Multimedia, Government, New chemical entity, Fine chemical

This strategic combination unites the strengths of these entities to provide a robust, North American-based supply chain solution for both clinical and commercial APIs and drug products.

Key Points: 
  • This strategic combination unites the strengths of these entities to provide a robust, North American-based supply chain solution for both clinical and commercial APIs and drug products.
  • View the full release here: https://www.businesswire.com/news/home/20240314509251/en/
    The strategic combination of Noramco, Purisys, and Halo Pharma unites the strengths of these entities to provide a robust, North American-based supply chain solution for both clinical and commercial APIs and drug products.
  • Lee Karras, CEO of the Noramco Group, emphasized the importance of this alignment in the current market, stating, "The COVID-19 pandemic exposed critical vulnerabilities in our drug supply chain.
  • To explore how the Noramco Group can support API to drug product supply needs, visit www.noramco.com .

Tempus Contributes De-Identified Cancer Data to Planned Data Enclave

Retrieved on: 
Thursday, March 14, 2024
Technology, Research, Software, Health, General Health, Data Management, Science, Artificial Intelligence, Oncology, Health informatics, NCI, Informatics, TCGA, Learning, Associate, Intelligence, Patient, API, Knowledge, National Cancer Institute, Information technology, Cancer, Doctor of Philosophy, MD, NIH, Medicine, Neoplasm, Bangladesh Technical Education Board, Data, The Cancer Genome Atlas, Medical imaging

This is a first of its kind contribution to NCI’s planned Data Enclave and will support the NCI’s mission of advancing cancer research by learning from each individual with cancer.

Key Points: 
  • This is a first of its kind contribution to NCI’s planned Data Enclave and will support the NCI’s mission of advancing cancer research by learning from each individual with cancer.
  • These de-identified data files with associated limited clinical information are derived from advanced-stage cancer patients sequenced with Tempus’ signature xT assay.
  • All summary level results returned to the users by the NCI Data Enclave will be openly accessible to the full cancer research community.
  • “This data will greatly expand the genomic data resources available to the cancer research community.

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline

Retrieved on: 
Tuesday, March 12, 2024
Other Health, Technology, Pharmaceutical, Mental Health, Infectious Diseases, Neurology, Artificial Intelligence, Clinical Trials, Other Technology, Science, Biotechnology, Alternative Medicine, Other Science, Health, Research, NCI, Agitation, Patient, Committee, National Cancer Institute, Virology, University, Quality of life, NIH, House, Myenteric plexus, Pancreatic Cancer Action Network, University of Maryland, Baltimore, Fetal alcohol spectrum disorder, IGC, IHV, Pharma, Jan Vansina, Bangladesh Technical Education Board, Therapy, Senate, Dementia, Public affairs, Pharmaceutical industry

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors.

Key Points: 
  • IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors.
  • Terry founded the Children’s Research Institute, one of America's top children’s research programs, the Pancreatic Cancer Action Network (PanCAN), and the National Organization on Fetal Alcohol Syndrome (NOFAS).
  • Ram Mukunda, CEO of IGC Pharma, commented, “With his track record of execution and extensive experience in health care, Mr. Lierman will undoubtedly bring invaluable insights and strategic guidance to IGC Pharma.
  • I look forward to collaborating with the talented team at IGC Pharma to drive forward the mission of bringing transformative therapies to patients in need.”

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

Retrieved on: 
Thursday, March 14, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Health Technology, Other Health, Disease, Risk, Patient, Necrotizing enterocolitis, Khosla Ventures, Infant, NIH, LBP, Johns Hopkins University, Therapy, Drug development, Symbiosis, Pharmaceutical industry

Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round.

Key Points: 
  • Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round.
  • The round, co-led by SymBiosis and Khosla Ventures, with participation of all existing investors, reflects enthusiasm for Siolta's approach to developing live microbiome-based therapeutics.
  • This financing is timely as Siolta continues to explore the potential of microbiome-based treatments in the areas of maternal and infant health.
  • Dr. Nikole E. Kimes, CEO and Co-founder of Siolta Therapeutics, commented on the funding: "This Series C financing is a key step for Siolta as we continue to develop STMC-103H in the clinic.